This Biotech’s Next Move Could Reshape the Sector, With 4 Others in Motion

One health giant is quietly building momentum behind an experimental treatment with breakout potential.

Analysts are watching closely as the next trial update approaches, and short-term setups are tightening. Here’s what traders are watching today, and 4 more stocks with fresh catalysts.

Never Miss a Stock Alert Again!

We now send our daily picks via SMS too — so you’ll get the same high-conviction ideas, even if you miss the email.

👉 Click here to get stock picks by text and stay in the loop, always.

Amgen | AMGN

Price: $301.33

Amgen is drawing new interest as it progresses with AMG 732, a first-in-class treatment targeting Thyroid Eye Disease (TED). The autoimmune disorder has limited options today, and this new therapy could significantly change the landscape.

The early Phase 1/2 trial uses a rigorous design with double masking and randomized assignment to ensure robust data.

Investors are watching technicals as closely as the science.

AMGN is consolidating around $300, and chart analysts see a 9.5% upside from current levels with low near-term risk. Institutional flow also appears to be picking up.

If results hit key safety or efficacy benchmarks, AMG 732 could become a pivotal asset in Amgen’s pipeline.

In a market hungry for defensiveness with upside, this setup checks both boxes.

Ranked First (Sponsored)

These 7 Stocks Were Built for the Next 30 Days — See Why

Every once in a while, timing and research align — and the result is a tight list of opportunities with immediate potential.

That’s exactly what’s inside this free report, featuring 7 of the strongest stock setups for the next 30 days.

These aren’t picked at random.

Each one cleared a tough set of criteria, screened from thousands of stocks based on earnings strength and momentum indicators.

Only the top 5% of our data made the first cut.

Then our analysts went even further — narrowing it down to the 7 companies with the most compelling case for a breakout.

This exclusive report is 100% free, but the window for optimal entry won’t stay open forever.

Click here now to claim your copy before the next wave of movement begins.

*This is a free resource from Zacks.com. Use of this material is subject to Zacks' Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. Nothing in this material is investment advice or a recommendation to buy, sell, or hold any security. Returns are based on hypothetical models with no transaction costs. The S&P 500 is an unmanaged index.

Starbucks | SBUX

Price: $92.78

Starbucks shares jumped 4% in after-hours trading following a solid revenue beat and signs of life in China.

While global same-store sales fell for the sixth consecutive quarter, CEO Brian Niccol emphasized that the turnaround plan is ahead of schedule.

The company is doubling down on customer service with its “Green Apron Service” and investing $500 million in labor over the next year.

Crucially, licensed stores on college campuses and in North America showed better-than-expected comps. Niccol pointed to improved partner engagement and a rebound in customer transactions, especially from non-loyalty members.

A new Rewards program and food innovation pipeline are on deck for 2026.

While investors may not yet see a complete comeback in the numbers, operational momentum suggests the worst may be over.

Visa | V

Price: $350.92

Visa’s Q2 numbers came in strong, with EPS of $2.98 and $10.17 billion in revenue, beating expectations. However, the company’s decision to maintain low-double-digit guidance sent shares down after the bell.

Analysts saw this as a cautious move rather than a red flag, especially with 8% growth in global payment volume and signs of healthy core spending.

What matters now is the back half of the year. Visa noted early evidence of consumers front-loading spending ahead of tariff hikes, which could mean softer numbers in Q4.

The company’s global footprint and essential nature of its services still make it a strong long-term hold.

Near-term, investors will be focused on cross-border volumes and how macro pressures impact guidance going forward.

Power Shift Profits (Sponsored)

6 Stocks Set to Soar Under New Policy Momentum

President Trump has sparked sweeping changes in Washington and the economy at large.

Billions of dollars are already shifting out of certain sectors and into others, creating significant wealth-building opportunities for investors.

To help you take full advantage, we're revealing the stocks we believe will climb the highest and fastest in our new Special Report, Presidential Profits: 6 Stocks to Ride Under the New Administration.

See 6 unexpected stocks poised for major breakouts FREE

Our previous presidential picks have given readers a chance to pocket significant gains, such as:

• +196% on First Solar

• +277% on Amplify Alternative Harvest ETF (after the 2020 election)

The recommendations in our new Presidential Profits report could spike just as quickly — and climb even higher.

Don't miss out on this rare opportunity. The Presidential Stock Report is only available until midnight tonight.

Download the Presidential Profits report now, absolutely free.

*This resource is provided by Zacks.com for informational purposes only. It is not investment advice. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is not a guarantee of future results. All investments carry risk. Information is subject to change. No recommendation or suitability is implied.

Corning | GLW

Price: $62.61

Corning delivered a breakout quarter, with revenue up 19% and EPS of $0.60, beating estimates. Its optical communications segment surged 41%, fueled by AI-related infrastructure demand.

Hedge-adjusted revenue came in at $4.05 billion, outpacing forecasts from Mizuho and Bloomberg.

Analysts are now calling for more upside.

Mizuho raised its target to $63, citing above-consensus Q3 guidance. JPMorgan and Citi remain bullish, particularly on the strength of optical enterprise sales, which are up 9% quarter-over-quarter.

The stock has rallied 33% year-to-date and is being discussed as a quiet AI winner. If Apple does launch a foldable iPhone in 2026, Corning is expected to be a primary beneficiary.

AstraZeneca | AZN

Price: $76.60

AstraZeneca’s Q2 results impressed, lifted by strong oncology sales and renewed U.S. demand. CEO Pascal Soriot reaffirmed guidance and pledged a $50 billion investment through 2030 focused on manufacturing and innovation.

With stateside expansion in full swing, the company is building its U.S. presence just as political attention turns toward pharma access and supply chains.

Soriot has positioned AstraZeneca as a global leader in cancer therapy and respiratory medicine. The company’s China business remains resilient, and it has avoided major tariff impacts so far.

For long-term investors, the steady results and large-scale vision create a stable base for future growth.

Near-term, continued strength in cancer drug demand and clarity on pricing regulation will shape sentiment.

The market is pausing after a record-breaking run, and traders are entering Wednesday focused on the Fed and earnings.

Futures are flat, and expectations for a rate hold sit near 98%. All eyes will be on Powell’s post-decision comments, particularly around inflation, tariffs, and the path forward.

Sector leadership may narrow, but analysts are now suggesting that earnings and AI optimism could still drive the S&P 500 higher into year-end.

Capital Economics and others have lifted their targets and noted that multiple sectors, not just tech, are revising earnings upward. This is creating a broader base for selective gains.

In this environment, setups like Amgen’s trial momentum or Corning’s AI-driven demand can lead to asymmetric returns. Starbucks’ execution, Visa’s steady core business, and AstraZeneca’s global growth plan all add diversity to the mix.

With the Fed, earnings, and geopolitics colliding this week, traders should keep their focus on real signals. That means strong execution, clear catalysts, and resilient demand.